Can extremely low LDL levels cause health problems?

While high LDL cholesterol is a well-known cardiovascular risk, extremely low levels below 40 mg/dL may increase risks for hemorrhagic stroke, depression, and certain cancers. Most people benefit from LDL levels between 50-70 mg/dL, balancing heart protection with other health considerations.

Questions on this topic?Ask Sai, our AI longevity expert.
Ask Sai

Understanding LDL Cholesterol and Its Role in Your Body

Low-density lipoprotein (LDL) cholesterol has earned its reputation as the "bad cholesterol" due to its association with cardiovascular disease. However, cholesterol isn't inherently evil—it's actually essential for numerous bodily functions. Your body uses cholesterol to produce hormones like testosterone and estrogen, create vitamin D, build cell membranes, and manufacture bile acids for digestion.

The key lies in balance. While elevated LDL levels can lead to arterial plaque buildup and increased heart disease risk, emerging research suggests that extremely low LDL levels might carry their own set of health concerns. This nuanced view challenges the "lower is always better" approach that has dominated cholesterol management for decades.

What Constitutes Extremely Low LDL Levels?

Medical professionals generally consider LDL levels below 100 mg/dL as optimal for heart health, with levels below 70 mg/dL recommended for individuals at high cardiovascular risk. However, "extremely low" typically refers to LDL levels below 40 mg/dL, though some studies examine effects at levels below 50 or even 30 mg/dL.

LDL Cholesterol Level Categories and Clinical Implications

LDL Level (mg/dL)CategoryClinical SignificanceTypical Management
Below 25<25Extremely LowMay increase hemorrhagic stroke risk; monitor for side effectsEvaluate medication necessity
25-4025-40Very LowExcellent CV protection; minimal concern for mostContinue treatment if tolerated
40-7040-70OptimalIdeal range for high-risk individualsMaintain current approach
70-10070-100Near OptimalGood for general populationLifestyle modifications
100-129100-129Above OptimalIncreased CV riskConsider treatment based on risk
Above 130>130HighSignificant CV riskMedication often recommended

LDL targets should be individualized based on overall cardiovascular risk profile and patient characteristics.

These ultra-low levels can occur naturally in some individuals due to genetic variations, but they're more commonly achieved through intensive statin therapy or newer cholesterol-lowering medications like PCSK9 inhibitors. Some people combining multiple cholesterol-lowering strategies may achieve LDL levels below 25 mg/dL. Understanding your cholesterol levels through regular testing helps ensure you're maintaining healthy ranges.

Here's how different LDL levels are typically categorized in clinical practice.

Potential Health Risks Associated with Very Low LDL

Hemorrhagic Stroke Risk

One of the most studied concerns regarding extremely low LDL levels is the potential increased risk of hemorrhagic stroke—bleeding in the brain. Multiple observational studies have found associations between very low cholesterol levels and increased hemorrhagic stroke risk, particularly in Asian populations. A large Japanese study published in the New England Journal of Medicine found that individuals with total cholesterol below 140 mg/dL had a higher risk of hemorrhagic stroke compared to those with moderate levels.

The proposed mechanism relates to cholesterol's role in maintaining blood vessel integrity. Extremely low cholesterol levels might weaken blood vessel walls, making them more prone to rupture. However, it's important to note that the absolute risk remains relatively small, and the cardiovascular benefits of lower LDL typically outweigh this risk for most people.

Mental Health and Cognitive Concerns

Several studies have explored connections between low cholesterol and mental health issues, including depression, anxiety, and aggressive behavior. The brain contains about 25% of the body's cholesterol, where it plays crucial roles in neurotransmitter function and cell membrane stability. Some research suggests that very low cholesterol levels might affect serotonin metabolism, potentially influencing mood and behavior.

Regarding cognitive function, the relationship appears complex. While high cholesterol in midlife is associated with increased dementia risk, some studies suggest that low cholesterol in elderly individuals might correlate with cognitive decline. However, these associations don't necessarily prove causation, and factors like overall health status and nutritional state may confound these relationships.

Cancer Risk Considerations

Observational studies have noted associations between low cholesterol levels and increased cancer risk, particularly for certain types like liver and blood cancers. However, this relationship is likely bidirectional—undiagnosed cancer can cause cholesterol levels to drop, making it appear that low cholesterol causes cancer when the reverse may be true. This phenomenon, known as reverse causation, complicates interpretation of these studies.

Large randomized controlled trials of cholesterol-lowering medications haven't shown increased cancer incidence, suggesting that pharmacologically lowered cholesterol doesn't increase cancer risk. Nevertheless, unexplained very low cholesterol levels, especially when occurring suddenly, may warrant investigation for underlying health conditions.

Who Might Be at Risk for Problems from Low LDL?

Certain populations may be more susceptible to potential adverse effects from extremely low LDL levels:

  • Elderly individuals, particularly those over 75, who may have different cholesterol needs than younger adults
  • People with a history of hemorrhagic stroke or bleeding disorders
  • Individuals with certain genetic conditions affecting cholesterol metabolism
  • Those with malnutrition or absorption disorders
  • People taking multiple cholesterol-lowering medications simultaneously

Additionally, women of childbearing age should be cautious about extremely low cholesterol levels, as cholesterol is essential for hormone production and fetal development. Pregnant women typically experience naturally elevated cholesterol levels to support fetal brain development.

The Importance of Context: Primary vs. Secondary Causes

When evaluating low LDL levels, healthcare providers distinguish between primary causes (genetic or medication-induced) and secondary causes (resulting from other health conditions). Secondary causes of low cholesterol can include:

  • Hyperthyroidism
  • Liver disease
  • Malabsorption syndromes
  • Certain cancers
  • Severe infections or sepsis
  • Malnutrition

If your LDL levels are unexpectedly low without cholesterol-lowering medication, your healthcare provider may investigate these potential underlying causes. This is why comprehensive health monitoring, including regular biomarker testing, provides valuable insights into your overall health status.

Balancing Cardiovascular Benefits with Potential Risks

For most people, the cardiovascular benefits of lower LDL levels far outweigh potential risks. Studies consistently show that reducing LDL cholesterol decreases heart attack and ischemic stroke risk. The IMPROVE-IT trial demonstrated that achieving LDL levels around 54 mg/dL provided additional cardiovascular benefit compared to levels around 70 mg/dL, without significant safety concerns.

However, the concept of a "floor effect" suggests there may be a point below which further LDL reduction provides no additional benefit. Current evidence suggests this threshold is likely around 25-40 mg/dL for most people, though individual variation exists. Healthcare providers increasingly adopt a personalized approach, considering factors like age, overall health status, and individual risk profiles when setting cholesterol targets.

Monitoring and Managing Your LDL Levels

If you're concerned about your LDL levels—whether too high or too low—regular monitoring provides essential information for optimal health management. Consider these strategies:

  • Get comprehensive lipid panels that include not just LDL, but also HDL, triglycerides, and increasingly, apolipoprotein B (ApoB) for a complete picture
  • Track trends over time rather than focusing on single measurements
  • Discuss your individual target ranges with your healthcare provider based on your overall risk profile
  • If on cholesterol-lowering medication, ensure regular follow-up to assess both efficacy and safety
  • Consider lifestyle factors that naturally support healthy cholesterol balance

For those achieving very low LDL levels through medication, most experts recommend continuing treatment if well-tolerated, as cardiovascular benefits typically outweigh theoretical risks. However, any concerning symptoms should prompt discussion with your healthcare provider about potentially adjusting your treatment approach.

Finding Your Optimal LDL Range

While the "lower is better" paradigm has merit for cardiovascular disease prevention, emerging evidence suggests that extremely low LDL levels may carry some risks for certain individuals. For most people, LDL levels between 50-70 mg/dL appear to offer excellent cardiovascular protection without significant concern for adverse effects. Those achieving levels below 40 mg/dL should ensure regular monitoring and maintain open communication with their healthcare providers.

Remember that cholesterol management is just one aspect of overall health optimization. A comprehensive approach including regular exercise, balanced nutrition, stress management, and routine health monitoring provides the best foundation for long-term wellness. Understanding your unique biomarker profile empowers you to make informed decisions about your health journey.

Frequently Asked Questions

How can I test my LDL cholesterol at home?

You can test your LDL cholesterol at home with [SiPhox Health's Heart & Metabolic Program](siphoxhealth.com/pricing/easydraw-heart-and-metabolic-program). This comprehensive program includes LDL cholesterol testing along with other crucial cardiovascular biomarkers, providing lab-quality results from the comfort of your home.

What LDL level is considered too low?

While there's no universally agreed-upon definition, LDL levels below 40 mg/dL are generally considered very low, and levels below 25 mg/dL are extremely low. Some studies suggest potential health concerns may emerge at these levels, though the cardiovascular benefits usually outweigh risks for most people.

Can diet alone cause dangerously low LDL levels?

It's extremely rare for diet alone to cause dangerously low LDL levels. Even very strict low-fat diets typically don't reduce LDL below 50-60 mg/dL. Extremely low levels are usually due to genetic factors, medications, or underlying health conditions rather than dietary choices.

Should I stop my statin if my LDL is very low?

Never stop or adjust your medication without consulting your healthcare provider. If you're concerned about very low LDL levels, discuss your concerns with your doctor. They can evaluate your individual risk-benefit profile and potentially adjust your treatment if necessary.

What's the difference between LDL and total cholesterol?

Total cholesterol includes LDL (bad cholesterol), HDL (good cholesterol), and VLDL (very low-density lipoprotein). LDL specifically refers to the cholesterol particles most associated with cardiovascular disease risk. Both measurements provide important information, but LDL is often the primary target for treatment.

References

  1. Navarese, E. P., Robinson, J. G., Kowalewski, M., et al. (2018). Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA, 319(15), 1566-1579.[Link][DOI]
  2. Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., & Cohen, J. D. (1989). Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. New England Journal of Medicine, 320(14), 904-910.[PubMed][DOI]
  3. Ravnskov, U., Diamond, D. M., Hama, R., et al. (2016). Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open, 6(6), e010401.[Link][DOI]
  4. Cannon, C. P., Blazing, M. A., Giugliano, R. P., et al. (2015). Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 372(25), 2387-2397.[PubMed][DOI]
  5. Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376(18), 1713-1722.[PubMed][DOI]
  6. Goldstein, L. B., Amarenco, P., Szarek, M., et al. (2008). Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Neurology, 70(24 Pt 2), 2364-2370.[PubMed][DOI]

Frequently Asked Questions

How can I test my LDL cholesterol at home?

You can test your LDL cholesterol at home with SiPhox Health's Heart & Metabolic Program. This comprehensive program includes LDL cholesterol testing along with other crucial cardiovascular biomarkers, providing lab-quality results from the comfort of your home.

What LDL level is considered too low?

While there's no universally agreed-upon definition, LDL levels below 40 mg/dL are generally considered very low, and levels below 25 mg/dL are extremely low. Some studies suggest potential health concerns may emerge at these levels, though the cardiovascular benefits usually outweigh risks for most people.

Can diet alone cause dangerously low LDL levels?

It's extremely rare for diet alone to cause dangerously low LDL levels. Even very strict low-fat diets typically don't reduce LDL below 50-60 mg/dL. Extremely low levels are usually due to genetic factors, medications, or underlying health conditions rather than dietary choices.

Should I stop my statin if my LDL is very low?

Never stop or adjust your medication without consulting your healthcare provider. If you're concerned about very low LDL levels, discuss your concerns with your doctor. They can evaluate your individual risk-benefit profile and potentially adjust your treatment if necessary.

What's the difference between LDL and total cholesterol?

Total cholesterol includes LDL (bad cholesterol), HDL (good cholesterol), and VLDL (very low-density lipoprotein). LDL specifically refers to the cholesterol particles most associated with cardiovascular disease risk. Both measurements provide important information, but LDL is often the primary target for treatment.

Related Articles

This article is licensed under CC BY 4.0. You are free to share and adapt this material with attribution.

Ask Questions About Any Health Topic

Chat with Sai, our AI health assistant, for personalized insights.

Click or drag file to upload blood test results

Backed By Leading Experts in Health Optimization

Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details